Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

CMV seropositivity is a potential novel risk factor for severe COVID-19 in non-geriatric patients

Simone Weber, Victoria Kehl, View ORCID ProfileJohanna Erber, Karolin I. Wagner, Ana-Marija Jetzlsperger, Theresa Burrell, Kilian Schober, Philipp Schommers, Max Augustin, Claudia S. Crowell, Markus Gerhard, Christof Winter, Christoph D. Spinner, View ORCID ProfileUlrike Protzer, Dieter Hoffmann, Elvira D’Ippolito, View ORCID ProfileDirk H Busch
doi: https://doi.org/10.1101/2021.12.22.21268268
Simone Weber
1Institute for Medical Microbiology, Immunology and Hygiene, Technical University of Munich, Munich, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Victoria Kehl
2Institute for AI and Informatics in Medicine, School of Medicine, Technical University of Munich, Munich, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Johanna Erber
3Department of Internal Medicine II, University Hospital Rechts Der Isar, School of Medicine, Technical University of Munich, Munich, Germany
8German Center for Infection Research (DZIF), partner site Munich, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Johanna Erber
Karolin I. Wagner
1Institute for Medical Microbiology, Immunology and Hygiene, Technical University of Munich, Munich, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ana-Marija Jetzlsperger
4Institute of Virology, School of Medicine, Technical University of Munich, Munich, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Theresa Burrell
1Institute for Medical Microbiology, Immunology and Hygiene, Technical University of Munich, Munich, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kilian Schober
5Mikrobiologisches Institut – Klinische Mikrobiologie, Immunologie und Hygiene, Universitäts-klinikum Erlangen, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, 91054 Erlangen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philipp Schommers
6Department I of Internal Medicine, Medical Faculty and University Hospital Cologne, University of Cologne, Cologne, Germany
7German Center for Infection Research (DZIF), partner site Bonn-Cologne, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Max Augustin
6Department I of Internal Medicine, Medical Faculty and University Hospital Cologne, University of Cologne, Cologne, Germany
7German Center for Infection Research (DZIF), partner site Bonn-Cologne, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claudia S. Crowell
1Institute for Medical Microbiology, Immunology and Hygiene, Technical University of Munich, Munich, Germany
8German Center for Infection Research (DZIF), partner site Munich, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Markus Gerhard
1Institute for Medical Microbiology, Immunology and Hygiene, Technical University of Munich, Munich, Germany
8German Center for Infection Research (DZIF), partner site Munich, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christof Winter
9Institute of Clinical Chemistry and Pathobiochemistry, School of Medicine, Technical University of Munich, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christoph D. Spinner
3Department of Internal Medicine II, University Hospital Rechts Der Isar, School of Medicine, Technical University of Munich, Munich, Germany
8German Center for Infection Research (DZIF), partner site Munich, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ulrike Protzer
4Institute of Virology, School of Medicine, Technical University of Munich, Munich, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ulrike Protzer
Dieter Hoffmann
4Institute of Virology, School of Medicine, Technical University of Munich, Munich, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elvira D’Ippolito
1Institute for Medical Microbiology, Immunology and Hygiene, Technical University of Munich, Munich, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dirk H Busch
1Institute for Medical Microbiology, Immunology and Hygiene, Technical University of Munich, Munich, Germany
8German Center for Infection Research (DZIF), partner site Munich, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Dirk H Busch
  • For correspondence: dirk.busch@tum.de
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background COVID-19 has so far affected more than 250 million individuals worldwide, causing more than 5 million deaths. Several risk factors for severe disease have been identified, most of which coincide with advanced age. In younger individuals, severe COVID-19 often occurs in the absence of obvious comorbidities. Guided by the finding of cytomegalovirus (CMV)-specific T cells with some cross-reactivity to SARS-CoV-2 in a COVID-19 intensive care unit (ICU) patient, we decided to investigate whether CMV seropositivity is associated with severe or critical COVID-19.

Methods National German COVID-19 bio-sample and data banks were used to retrospectively analyze the CMV serostatus of patients who experienced mild (n=101), moderate (n=130) or severe to critical (n=80) disease by CMV IgG serology. We then investigated the relationship between disease severity and CMV serostatus via statistical models.

Results Non-geriatric patients (< 70 years) with severe COVID-19 were found to have a very high prevalence of CMV-seropositivity, while CMV status distribution in individuals with mild disease was similar to the prevalence in the German population; interestingly, this was not detectable in older patients. Prediction models support the hypothesis that the CMV serostatus might be a strong biomarker in identifying younger individuals with a higher risk of developing severe COVID-19.

Conclusions We identified ‘CMV-seropositivity’ as a potential novel risk factor for severe COVID-19 in non-geriatric individuals in the studied cohorts. More mechanistic analyses as well as confirmation of similar findings in cohorts representing the currently most relevant SARS-CoV-2 variants should be performed shortly.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study was supported by the EIT Health CoViproteHCt #20877 and the German National Network of University Medicine of the Federal Ministry of Education and Research (BMBF; NaFoUniMedCovid19, 01KX2021; COVIM).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Approval for the study design and sample collection was obtained from the local ethics committee of the Technical University of Munich (reference number 182/20 and 633/21 S-SR) and the COVIM steering committee.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ↵* co-first authors

  • ↵§ co-senior authors

Data Availability

All data produced in the present study are available upon reasonable request to the authors

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted December 24, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
CMV seropositivity is a potential novel risk factor for severe COVID-19 in non-geriatric patients
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
CMV seropositivity is a potential novel risk factor for severe COVID-19 in non-geriatric patients
Simone Weber, Victoria Kehl, Johanna Erber, Karolin I. Wagner, Ana-Marija Jetzlsperger, Theresa Burrell, Kilian Schober, Philipp Schommers, Max Augustin, Claudia S. Crowell, Markus Gerhard, Christof Winter, Christoph D. Spinner, Ulrike Protzer, Dieter Hoffmann, Elvira D’Ippolito, Dirk H Busch
medRxiv 2021.12.22.21268268; doi: https://doi.org/10.1101/2021.12.22.21268268
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
CMV seropositivity is a potential novel risk factor for severe COVID-19 in non-geriatric patients
Simone Weber, Victoria Kehl, Johanna Erber, Karolin I. Wagner, Ana-Marija Jetzlsperger, Theresa Burrell, Kilian Schober, Philipp Schommers, Max Augustin, Claudia S. Crowell, Markus Gerhard, Christof Winter, Christoph D. Spinner, Ulrike Protzer, Dieter Hoffmann, Elvira D’Ippolito, Dirk H Busch
medRxiv 2021.12.22.21268268; doi: https://doi.org/10.1101/2021.12.22.21268268

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (241)
  • Allergy and Immunology (521)
  • Anesthesia (125)
  • Cardiovascular Medicine (1425)
  • Dentistry and Oral Medicine (217)
  • Dermatology (158)
  • Emergency Medicine (292)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (585)
  • Epidemiology (10307)
  • Forensic Medicine (6)
  • Gastroenterology (528)
  • Genetic and Genomic Medicine (2637)
  • Geriatric Medicine (254)
  • Health Economics (497)
  • Health Informatics (1740)
  • Health Policy (790)
  • Health Systems and Quality Improvement (676)
  • Hematology (268)
  • HIV/AIDS (568)
  • Infectious Diseases (except HIV/AIDS) (12103)
  • Intensive Care and Critical Care Medicine (649)
  • Medical Education (273)
  • Medical Ethics (83)
  • Nephrology (291)
  • Neurology (2466)
  • Nursing (145)
  • Nutrition (379)
  • Obstetrics and Gynecology (493)
  • Occupational and Environmental Health (568)
  • Oncology (1327)
  • Ophthalmology (403)
  • Orthopedics (147)
  • Otolaryngology (238)
  • Pain Medicine (168)
  • Palliative Medicine (51)
  • Pathology (343)
  • Pediatrics (784)
  • Pharmacology and Therapeutics (330)
  • Primary Care Research (296)
  • Psychiatry and Clinical Psychology (2405)
  • Public and Global Health (5018)
  • Radiology and Imaging (895)
  • Rehabilitation Medicine and Physical Therapy (530)
  • Respiratory Medicine (682)
  • Rheumatology (309)
  • Sexual and Reproductive Health (256)
  • Sports Medicine (246)
  • Surgery (298)
  • Toxicology (45)
  • Transplantation (141)
  • Urology (108)